Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 408

Sort by

Sort Order Select

Journal Articles

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-140441

Published: 2020

Journal Articles

Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

Mariela Sivina, Nitin Jain, MD, Ekaterina Kim, PhD, Tapan M. Kadia, MD, Zeev E. Estrov, MD, Maro Ohanian, DO, Michael Andreeff, MD PhD, Mathew Thomas, Philip A. Thompson, MB, MS, Hagop M. Kantarjian, MD, Michael J. Keating, MBBS, Susan M. O'Brien, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141014

Published: 2020

Journal Articles

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

Bing Z Carter, PhD, Po Yee Mak, Vivian Ruvolo, MS, Wenjing Tao, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141399

Published: 2020

Journal Articles

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MDPhD, Kaori Saito, Haeun Yang, Vivian Ruvolo, MS, Po Yee Mak, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Hironori Harada, MD PhD, Kazuhiro Katayama, PhD, Takashi Miida, MD PhD, Marina Konopleva, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136587

Published: 2020

Journal Articles

Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in Acute Myeloid Leukemia

Rasoul Pourebrahim, MDPhD, Rafael Heinz Montoya, BS, Zoe Alaniz, Lauren B Ostermann, BS, Hung Alex Luong, Joseph D. Khoury, MD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142523

Published: 2020

Journal Articles

Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2020) 136 (Supplement 1): 7–9.

https://doi.org/10.1182/blood-2020-141075

Published: 2020

Journal Articles

Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma

Hussein A Abbas, MDPhD, Patrick K Reville, MD, Alexis Geppner, Maro Ohanian, DO, Koji Sasaki, MD, Gautam Borthakur, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Carlos E. Bueso-Ramos, MD PhD, Michael Andreeff, MD PhD, Nicholas J. Short, MD, Sherry A. Pierce, BSN, BA, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-138459

Published: 2020

Journal Articles

Combined Blockage of E-Selectin and CXCR4 (GMI-1359) Enhances Anti-Leukemia Effect of FLT3 Inhibition (Sorafenib) and Protects Hematopoiesis in Pre-Clinical AML Models

Weiguo Zhang, MD PhD, Kyung Hee Chang, PhD, Mahesh Basyal, BS, Yannan Jia, Lauren B Ostermann, BS, William E. Fogler, PhD, John L. Magnani, PhD, M Anna Zal, BS., MS, Tomasz Zal, PhDMSc, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-140984

Published: 2020

Journal Articles

Venetoclax Enhances Anti-Leukemia Activity of CD123-Specific BiTE-Secreting T-Cells in AML

Hong Mu-Mosley, MDPhD, Lauren B Ostermann, BS, Ran Zhao, BS, Challice L. Bonifant, MDPhD, Stephen Gottschalk, MD, Mireya Paulina Velasquez, MD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-139625

Published: 2020

Journal Articles

Dual CXCR4 and E-Selectin Inhibition (GMI-1359) Rapidly Increases AML Cellular Motility Prior to Intravasation and Vascular Niche Depletion Observed By Intravital Bone Marrow Two-Photon Microscopy

Tomasz Zal, PhDMSc, Malgorzata Anna Zal, MSc, Mateusz Rytelewski, PhD, Kyung Hee Chang, PhD, Rodrigo Jacamo, PhD, William E. Fogler, PhD, John L. Magnani, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-143420

Published: 2020

Journal Articles

Clonal Expansion of Mutant p53 Clones By MDM2 Inhibition in Acute Myeloid Leukemias

Yuki Nishida, MDPhD, Rafael Heinz Montoya, BS, Kiyomi Morita, MDPhD, Tomoyuki Tanaka, MDPhD, Feng Wang, PhD, Koichi Takahashi, MD PhD, Jo Ishizawa, MDPhD, Prasanna Kumar, PhD, Parul Patel, PhD, Cedric E. Dos Santos, PhD, Courtney D. DiNardo, MD MSCE, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142794

Published: 2020

Journal Articles

Osterix Marks a Distinct Population of Circulatory Bone Marrow Mesenchymal Stem Cells That Is Increased upon Oncogenic Stress

Rafael Heinz Montoya, BS, Rasoul Pourebrahim, Zoe Alaniz, BS, Lauren B Ostermann, BS, Jared K. Burks, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-142713

Published: 2020

Journal Articles

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

Daniel Rivera, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Marina Konopleva, MD PhD, Rashmi Kanagal-Shamanna, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Koichi Takahashi, MD PhD, Elias Jabbour, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Sherry A. Pierce, BSN, BA, Michael Andreeff, MD PhD, Kapil N. Bhalla, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Tapan M. Kadia, MD

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-142043

Published: 2020

Journal Articles

AML Cells Alter Bone Homeostasis By Promoting the Formation of Immature Bone and Resorption of Mature Bone That Supports Leukemia Progression

Anudishi Tyagi, PhD, Bin Yuan, Stanley Ly, Fouad El-Dana, MD, Vinitha Mary Kuruvilla, MSc, Qi Zhang, PhD, Christine B Peterson, Xin Zhou, PhD, Benoit deCrombrugghe, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD, Behrang Amini, MD PhD, Venkata Lokesh Battula, PhD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-142777

Published: 2020

Journal Articles

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141411

Published: 2020

Journal Articles

High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML

Muharrem Muftuoglu, MD, Po Yee Mak, Vivian Ruvolo, MS, Yuki Nishida, MDPhD, Peter P. Ruvolo, PhD, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-143371

Published: 2020

Journal Articles

Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias

Yuki Nishida, MDPhD, Jo Ishizawa, MDPhD, Edward Ayoub, PhD MS, BSc, Rafael Heinz Montoya, BS, Vivian Ruvolo, MS, Kensuke Kojima, MD PhD, Naval Daver, MD, Arnaud Lesegretain, Sharon Shacham, PhD MBA, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-140768

Published: 2020

Journal Articles

Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy

Kelly S. Chien, MD, Gautam Borthakur, MD, Kiran Naqvi, MD MPH, Naval Daver, MD, Guillermo Montalban Bravo, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MD MSCE, Elias Jabbour, MD, Yesid Alvarado, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly A. Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-141100

Published: 2020

Journal Articles

High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomitant Analysis of Cell Surface Antigens, Signaling Pathways and Anti-Apoptotic Proteins

Muharrem Muftuoglu, MD, Zoe Alaniz, BS, Duncan Mak, BSc, MPhil, Angelique J. Lin, MS, Jared K. Burks, PhD, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-143432

Published: 2020

Journal Articles

Inhibition of EZH1 and EZH2 Restores Chemosensitivity of Leukemia Stem Cells in Acute Myeloid Leukemia By Recruitment of Quiescent AML Stem/Progenitor Cells

Kyung Hee Chang, PhD, Zoe Alaniz, Yuki Nishida, MDPhD, Cedric E. Dos Santos, PhD, Eric Slosberg, PhD, Naval Daver, MD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142071

Published: 2020

NARROW

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in Acute Myeloid Leukemia

Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma

Combined Blockage of E-Selectin and CXCR4 (GMI-1359) Enhances Anti-Leukemia Effect of FLT3 Inhibition (Sorafenib) and Protects Hematopoiesis in Pre-Clinical AML Models

Venetoclax Enhances Anti-Leukemia Activity of CD123-Specific BiTE-Secreting T-Cells in AML

Dual CXCR4 and E-Selectin Inhibition (GMI-1359) Rapidly Increases AML Cellular Motility Prior to Intravasation and Vascular Niche Depletion Observed By Intravital Bone Marrow Two-Photon Microscopy

Clonal Expansion of Mutant p53 Clones By MDM2 Inhibition in Acute Myeloid Leukemias

Osterix Marks a Distinct Population of Circulatory Bone Marrow Mesenchymal Stem Cells That Is Increased upon Oncogenic Stress

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

AML Cells Alter Bone Homeostasis By Promoting the Formation of Immature Bone and Resorption of Mature Bone That Supports Leukemia Progression

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML

Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias

Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy

High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomitant Analysis of Cell Surface Antigens, Signaling Pathways and Anti-Apoptotic Proteins

Inhibition of EZH1 and EZH2 Restores Chemosensitivity of Leukemia Stem Cells in Acute Myeloid Leukemia By Recruitment of Quiescent AML Stem/Progenitor Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only